Confocal Laser Endomicroscopy in Patients With Eosinophilic Esophagitis
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Confocal laser endomicroscopy enables in vivo microscopic imaging within the mucosa layer of the gut at a subcellular resolution. Various studies have addressed the potential of endomicroscopy for the in vivo diagnosis of esophageal squamous cell carcinoma, Barrett´s esophagus and esophageal adenocarcinoma. Currently, there is only one case report from our group who noted the utility of endomicroscopy for the in vivo diagnosis of eosinophilic esophagitis.
The purpose of this study is to determine whether endomicroscopy is effective for the in vivo diagnosis of eosinophilic esophagitis.
| Condition | Intervention |
|---|---|
|
Eosinophilic Esophagitis. |
Device: Confocal laser endomicroscopy |
| Study Type: | Observational |
| Study Design: | Time Perspective: Prospective |
| Official Title: | Confocal Laser Endomicroscopy in Patients With Eosinophilic Esophagitis |
- Effectiveness of endomicroscopy for the in vivo diagnosis of eosinophilic esophagitis [ Time Frame: November 2010 - November 2012 ] [ Designated as safety issue: Yes ]
- Differentiation of mucosal alterations in patients with eosinophilic esophagitis compared to patients with gastroesophageal reflux disease. [ Time Frame: November 2010 - November 2012 ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 45 |
| Study Start Date: | November 2010 |
| Estimated Study Completion Date: | December 2014 |
| Estimated Primary Completion Date: | November 2014 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
| Control patients |
Device: Confocal laser endomicroscopy
Confocal laser endomicroscopy
|
| Patients with eosinophilic esophagitis |
Device: Confocal laser endomicroscopy
Confocal laser endomicroscopy
|
Eligibility| Ages Eligible for Study: | 18 Years to 85 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Probability Sample |
Patients with eosinophilic esophagitis who underwent EGD for the evaluation of their symptoms.
Control patients who underwent EGD because of other reasons.
Inclusion Criteria:
- Written informed consent
- Age 18-85 years
- Ability of subjects to understand character and individual consequences of clinical trial
- Subjects undergoing EGD
Exclusion Criteria:
- Inability to provide written informed consent
- Severe Coagulopathy (Prothrombin time < 50% of control, Partial thromboplastin time > 50 s)
- Impaired renal function (Creatinine > 1.2 mg/dl)
- Pregnancy or breast feeding
- Active gastrointestinal bleeding
- Known allergy to fluorescein, acriflavin or cresyl violet
- Residing in institutions (e.g. prison)
Contacts and Locations| Contact: Markus F. Neurath, M.D., Ph.D. | 4991318535204 | markus.neurath@uk-erlangen.de |
| Contact: Helmut Neumann, M.D., Ph.D. | 4991318535204 | helmut.neumann@uk-erlangen.de |
| Germany | |
| University of Erlangen-Nuremberg | Recruiting |
| Erlangen, Bayern, Germany, 91054 | |
| Contact: Helmut Neumann, M.D., Ph.D. 4991318535204 helmut.neumann@uk-erlangen.de | |
| Principal Investigator: Helmut Neumann, M.D., Ph.D. | |
| Study Director: | Markus F. Neurath, M.D., Ph.D. | University of Erlangen-Nuremberg |
| Principal Investigator: | Helmut Neumann, M.D., Ph.D. | University of Erlangen-Nuremberg |
More Information
No publications provided
| Responsible Party: | Helmut Neumann, Professor, University of Erlangen-Nürnberg Medical School |
| ClinicalTrials.gov Identifier: | NCT01234376 History of Changes |
| Other Study ID Numbers: | HN-0003 |
| Study First Received: | November 2, 2010 |
| Last Updated: | January 23, 2013 |
| Health Authority: | Germany: Ethics Commission |
Additional relevant MeSH terms:
|
Esophagitis Eosinophilic Esophagitis Esophageal Diseases Gastrointestinal Diseases Digestive System Diseases Gastroenteritis |
Eosinophilia Leukocyte Disorders Hematologic Diseases Hypersensitivity, Immediate Hypersensitivity Immune System Diseases |
ClinicalTrials.gov processed this record on May 16, 2013